0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Effects of New Topical β-Mimetic (Isoxuprine and Nylidrine) and β-Lytic (Oxprenolol) Agents on the Ocular Pressure in Glaucomatous Eyes

      Ophthalmic Research

      S. Karger AG

      Glaucoma, Ocular hypotension, β-mimetic and β-lytic drugs, Topical therapy

      Read this article at

      ScienceOpenPublisher
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Topical administrations of 1 % solution of both isoxuprine, nylidrin (β-mimetic agents) and of oxprenolol (β-lytic) were found effective in decreasing the intraocular pressure in glaucomatous eyes. No change of the systemic blood pressure occurred. After 8–10 days of treatment with two daily administration, tachyphylaxis begun to be noticed in most cases. Oxprenolol is a nonselective β-receptor-blocking agent, with an intrinsic sympathomimetic activity and a membrane activity. Its administration in 1% solution produced, in glaucomatous eyes, a drop of the ocular pressure with maximum peaks at the 2nd and 3rd hours, and a complete recovery 6–12 h later. A slight myosis was present in 4 of the 6 treated patients. Systemic blood pressure remained unchanged.

          Related collections

          Author and article information

          Journal
          ORE
          Ophthalmic Res
          10.1159/issn.0030-3747
          Ophthalmic Research
          S. Karger AG
          0030-3747
          1423-0259
          1977
          1977
          03 December 2009
          : 9
          : 4
          : 238-246
          Affiliations
          University Eye Clinic of Rome, Rome
          Article
          264891 Ophthalmic Res 1977;9:238–246
          10.1159/000264891
          © 1977 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 9
          Categories
          Paper

          Comments

          Comment on this article